Abstract:Melanoma is an invasive and malignant type of tumor with unsatisfactory therapeutic outcomes. The present study aimed to detect the expression levels of microRNA (miR)-125b in formalin-fixed paraffin-embedded (FFPE) melanoma tissues and the association of its expression levels with the clinical features, diagnosis and prognosis of melanoma. Expression levels of miR-125b in 29 FFPE melanoma specimens (16 primary and 13 metastatic tumors), and 16 intradermal nevus (IDN) specimens as a control, were detected by reverse transcription-quantitative PCR. Associations among miR-125b expression and mortality, patient age and sex, tumor location and size, lymph node metastasis (LNM) and TNM stage were analyzed by t-test. The diagnostic value of miR-125b for melanoma was evaluated by receiver operating characteristic (ROC) curve analysis. Prognosis of patients in the microRNA-125b low- and high-expression groups was analyzed by Fisher's exact test. The association between miR-125b expression and the overall survival of patients with melanoma was assessed using Kaplan-Meier curve analysis and a Cox proportional hazards model. The results revealed that the expression levels of miR-125b in primary and metastatic melanomas were significantly lower than those in the IDN control group (P<0.05), and the expression levels of miR-125b in the metastatic group were significantly lower than those in the primary group (P<0.05). In addition, the expression levels of miR-125b were significantly associated with LNM (P=0.001) and TNM stage (P=0.004), but not with age, sex, tumor size or location (P>0.05). ROC curve analysis revealed that the area under the curve (AUC) was 0.880, with a 95% CI of 0.777-0.984 (P<0.05). The overall survival rate of the patients with a low expression level of miR-125b (20.0%) was lower than that of patients with a high expression level of miR-125b (64.3%) (P<0.05). miR-125b expression was an independent predictor of overall survival in patients with melanoma [hazard ratio (HR), 0.252; 95% CI, 0.087-0.729]. Overall, these findings indicated that a low expression level of miR-125b was associated with higher LNM and TNM stage in patients with melanoma, and that this has a certain diagnostic value. miR-125b may be used for the early screening of melanoma and determining the prognosis of patients with melanoma, and may be a potential target for the treatment of the disease.

MicroRNA-125a-3p Downregulation Correlates with Tumorigenesis and Poor Prognosis in Patients with Non-Small Cell Lung Cancer

P2.03b-079 Decreased Expression of miR-125a-3p is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients

P2.03b-079 Decreased Expression of miR-125a-3p is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients: Topic: Biomarkers

MiR-125b Promotes Cell Migration and Invasion by Targeting PPP1CA-Rb Signal Pathways in Gastric Cancer, Resulting in a Poor Prognosis

Prognostic Implications of Decreased Microrna-101-3p Expression in Patients with Non-Small Cell Lung Cancer

MicroRNA-125b Promotes Tumor Metastasis Through Targeting Tumor Protein 53-Induced Nuclear Protein 1 in Patients with Non-Small-cell Lung Cancer

Downregulation of Mir-125B-5p and Its Prospective Molecular Mechanism in Lung Squamous Cell Carcinoma.

MicroRNA-1253 Suppresses Cell Proliferation and Invasion of Non-Small-cell Lung Carcinoma by Targeting WNT5A

Down-regulation of Microrna-125B-2-3p is a Risk Factor for a Poor Prognosis in Hepatocellular Carcinoma

MicroRNA-125b may function as an oncogene in lung cancer cells.

Down-regulation of Microrna-144-3p and Its Clinical Value in Non-Small Cell Lung Cancer: a Comprehensive Analysis Based on Microarray, Mirna-Sequencing, and Quantitative Real-Time PCR Data

Elevated Microrna-125B Levels Predict a Worse Prognosis in HER2-positive Breast Cancer Patients

Association Between Microrna-125B Expression in Formalin-Fixed Paraffin-Embedded Tumor Tissues and Prognosis in Patients with Melanoma.

Prognostic Value of Microrna-125 in Various Human Malignant Neoplasms: A Meta-Analysis

MicroRNA-383 is a Tumor Suppressor and Potential Prognostic Biomarker in Human Non-Small Cell Lung Caner.

Identification of Mir-124A As a Novel Diagnostic and Prognostic Biomarker in Non-Small Cell Lung Cancer for Chemotherapy

Reduced Mir-125A Levels Associated with Poor Survival of Patients with Hepatocellular Cancer

Hsa-miR-125a-3p and Hsa-Mir-125a-5p Are Downregulated in Non-Small Cell Lung Cancer and Have Inverse Effects on Invasion and Migration of Lung Cancer Cells.

Elevation of miR-125b-5p is related to improved prognosis in laryngeal squamous cell carcinoma and inhibits the malignancy and glycometabolic disorder by targeting MAP3K9

MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer Patients

Deregulated Expression of Mir-21, Mir-143 and Mir-181A in Non Small Cell Lung Cancer is Related to Clinicopathologic Characteristics or Patient Prognosis